Collectively, our findings support the existence of a FHC-ROS-NF-κB axis, which would account for the acquired chemoresistant phenotype in K562 and SKOV3 cell line models, encourages a deeper investigation of the correlation between FHC expression in cancer tissues and clinical outcomes, and highlights the potentiality of FHC in cancer therapy. This evidence concerns the gene NFKB1 and cancer.